Pharmaceutical Executive
December 12, 2014
Features
0
0
The science of drug discovery is back on script-and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?
November 01, 2014
Column
0
0
Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.
November 01, 2014
Column
0
0
Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
November 01, 2014
Features
0
0
By rethinking the role of the sales rep and the new skills it demands, pharma companies can put themselves in a prime competitive position.
November 01, 2014
Column
0
0
The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.
November 01, 2014
Column
0
0
Treatment Action Group (TAG) reaches a milestone in improving access to much-needed treatments for tuberculosis.
November 01, 2014
From the Editor
0
0
Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.
November 01, 2014
Features
0
0
Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.